Purpose Evidence is limited on implementation of secondary prevention guidelines for coronary heart disease (CHD) in clinical practice and variations between younger and elder patients. We investigated the control of cardiovascular risk factors in German patients with CHD enrolled in the European-wide EUROASPIRE IV survey, stratified by younger (18-69 years) and older (70-79 years) age groups. Method Eligible subjects were identified via the hospitals' patient information system and invited to attend a study visit 6 months to 3 years after hospitalization for CHD (myocardial infarction, ischemia, angioplasty/stent, coronary bypass grafting Conclusion Although most CHD patients received the drug classes recommended by guidelines, treatment goals were frequently not achieved. Elderly subjects had a less favorable pattern, which may reflect multi-morbidity and weaker identification with treatment targets. National CHD prevention strategies should focus not only on enhancing lifestyle modifications and reaching treatment targets, but also on highlighting the different needs in older individuals.
Introduction
The main purposes of medical treatment in patients with coronary heart disease (CHD) are to adequately control the risk factors of disease progression, such as hypertension, dyslipidemia, diabetes, overweight/obesity, and smoking, and to aim for an overall healthy lifestyle [1] . However, previous studies showed that implementation of guideline recommendations for appropriate preventive measures in daily clinical practice remains suboptimal [2, 3] .
The European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) surveys-a multinational initiative of the European Society of Cardiology (ESC)-addressed guideline implementation in clinical practice in CHD patients in three previous phases since 1995 [4] [5] [6] . In the current EUROASPIRE IV survey, 7998 patients with CHD aged 18 to 79 years from 24 European countries were examined between 2012 and 2013 [3] . The main results indicated insufficient control of established risk factors, albeit the majority of patients is now treated with anti-platelet drugs, statins, and beta-blockers. Many CHD patients also still smoke, and the prevalence of low physical activity as well as of overweight/obesity is increasing. However, considerable variability of risk factors and secondary prevention therapy was observed between participating European countries [3] .
Due to the gain in life expectancy in Western countries [7] , the absolute number of older patients with CV risk factors and established CHD will increase in the next decades. The optimal strategy for secondary CHD prevention in the elderly is widely discussed, as evidence is much less conclusive as compared to younger individuals [8, 9] . Therapeutic care in the elderly has to consider on one hand treatment targets that have been shown to reduce adverse outcomes, such as tight target levels for blood pressure and lipids, but also a per se lower level of physical activity, accumulations of other comorbid conditions, and drug-interactions and polypharmacy in this multi-morbid population [7, 10] . Only few studies reported on differences in CHD risk factor control between younger and elder patients [11] [12] [13] .
Therefore, we report the main results of quality of CHD care in secondary prevention at the German study center of the EUROASPIRE IV survey. We apply current updated guideline recommendations by the ESC [1] and the German Society of Cardiology [14] and analyze potential variations in risk factor control between younger (< 70 years) and older (70 to 79 years) patients.
Methods Patient Population
The principle results including the methodology of the Bhospital-arm^of the entire EUROASPIRE IV survey have been published previously [3] . Patients between 18 and 79 years of age with CHD were invited to attend a study visit if they had been admitted due to a coronary event (coronary artery bypass grafting [CABG] , percutaneous coronary intervention [PCI] , acute myocardial infarction [MI] , or myocardial ischemia, the latter two receiving conservative therapy without intervention) in 6-36 months prior to the anticipated study visit. The latest event during the hospital stay was used for index classification. At the German study center, participants were recruited from the Dept. of Medicine I, the Dept. of Cardiovascular Surgery, University Hospital Würzburg, and the Dept. of Medicine, Klinik Kitzinger Land. Eligible subjects were identified through the hospitals' medical records and consecutively invited by up to three postal letters.
Data Collection
At the study visit, detailed information on medical history, medication, lifestyle, and behavior were collected, and measurements (e.g., blood pressure, weight, height, carbon monoxide [CO] in exhaled air, oral glucose tolerance testing [OGTT], blood draw, preferably in participants fasting) were performed according to EUROASPIRE IV standards [3] . Study participants also consented in retrospective chart review of their index hospitalization to obtain information on the index event, risk factors, medication, and clinical measurements.
Data Management
Management regarding data requested by the EUROASPIRE IV protocol was provided by the EURObservationalResearch Programme (Nice, France). These data were entered into web-based case report forms (CRF) using unique identification numbers. After data had been centrally checked for completeness and plausibility, a copy of the German data was sent to our study center, where it was connected to an electronic database that includes additional local data, which were collected on pseudonymized paper-based CRFs.
Ethics
All patients provided written informed consent to take part in the study. The study was approved by the Ethics Committee of the Medical Faculty, University of Würzburg (Vote 58/12) and by the data protection officer of the University of Würzburg and the University Hospital Würzburg.
Definitions
We stratified patients into younger (< 70 years) and older (≥ 70 years) age groups, which was near the median age in our sample and provided roughly equal sample sizes of the age groups. Uncontrolled blood pressure, regardless of hypertensive treatment, was defined as suggested by the German Society of Cardiology [15] as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. Cutoff values differed for patients with self-reported diabetes (systolic ≥ 140 mmHg, diastolic ≥ 85 mmHg), patients > 80 years (systolic ≥ 150 mmHg, diastolic ≥ 90 mmHg), and patients with chronic kidney disease (albumin/creatinine ratio ≥ 300 mg/g) (systolic ≥ 130 mmHg, diastolic ≥ 90 mmHg).
Dyslipidemia was described as LDL cholesterol ≥ 2.5 mmol/l (≥ 100 mg/dl) and also as LDL cholesterol ≥ 1.8 mmol/l (≥ 70 mg/dl) [1] . Classification of overweight (body mass index [BMI] ≥ 25 kg/m 2 ) and obesity (≥ 30 kg/m 2 ) was based on weight and height, abdominal overweight (female ≥ 80 cm/male ≥ 94 cm), and central obesity (female ≥ 88 cm/male ≥ 102 cm) on waist circumference [16] . CO values of > 10 ppm in exhaled air were suggestive of current smoking even if self-reported smoking was denied [17] . Adequate glycemic control in diabetic patients was defined as HbA1c < 7.0% [1] .
Data Availability
The datasets generated and/or analyzed during the current study are property of the European Society of Cardiology and are not publicly available.
Statistical Methods
Analyses were performed using SPSS 21 (IBM Corporation, NY, USA) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA). 
Results

Patient Population
Between August 2012 and March 2013, a total of n = 1380 persons were invited, of which n = 536 were recruited (response rate 38.8%). At the study visit, median age of the participants was 68. A platelet-inhibiting agent was prescribed in 89% of the patients ( Table 2 ). Patients of older age received platelet inhibitors less often (83.8 vs. 93.1%, p < 0.001), but were more often on anticoagulation therapy (7.3 vs. 2.7%, p = 0.01). Similar numbers were observed for beta-blocker therapy, i.e., 83.4% of all patients, 79.1% in older vs. 86.8% in younger patients (p = 0.02). No difference between age groups was evident for the use of lipid-lowering treatment in general (total 84.7%) or statin therapy in particular (total 83.2%). All three substance classes primarily recommended for CHD (i.e., platelet inhibitor, beta-blocker, statin) were prescribed in 65.5% of patients, 72.5% younger vs. 56.4% in older patients (p < 0.001).
Overweight/Obesity and Smoking
Overweight was self-reported by 44.4% of the participants (Table 1 ), but 85.3% were overweight and 36.7% were obese based on BMI categories. Older patients were less likely to be obese as compared to younger individuals (30.7 vs. 41.2%, p = 0.01). Ten percent reported to be active smokers, with 2.6% older patients vs. 16.6% younger patients (p < 0.001). An additional eight self-reporting non-smokers (1.7%) had CO levels > 10 ppm, i.e., indicative for smoking. These were mainly younger individuals (2.8 vs. 0.4%, p = 0.07). 
Blood Pressure
Hypertension was self-reported by 72.2% (Table 1) , with no differences between age groups. Yet, 95.7% were treated with at least one antihypertensive drug (beta-blocker, any diuretic, ACE/ARB inhibition, calcium channel blocker, others). Median blood pressure differed between older and younger patients (140/79 vs. 131/81 mmHg, p < 0.01). About 45% of all patients were not within the recommended blood pressure targets (Table 3a) , with similar numbers in patients with selfreported hypertension and those treated with at least one antihypertensive drug. Patients of older age were more likely to be hypertensive (about 50 vs. 40%, p < 0.05).
Dyslipidemia
Hyperlipidemia was reported by 60.8% of participants (Table 1) . Median fasting total cholesterol was 4.46 mmol/l (172 mg/dl) and LDL cholesterol levels were 2.54 mmol/l (98 mg/dl). Cholesterol levels were slightly higher in younger patients as compared to older patients (p < 0.05). About half of all patients had the recommended LDL levels < 2.5 mmol/l (~100 mg/dl) (Table 3b) , with no major differences between age groups or between patients with self-reported hyperlipidemia or on any lipid-lowering drug. By contrast, only very few patients (about 10%) reached LDL levels of < 1.8 mmol/l (< 70 mg/dl).
Diabetes Mellitus
Every fourth patient reported on diabetes mellitus (1.1% type 1 and 24.1% type 2) and 2% had an impaired fasting glucose (IFG)/impaired glucose tolerance (IGT), with no significant differences between age groups (Table 1) . Of diabetic patients, 54.1% were treated with oral anti-glycemic drugs alone, 9.6% received insulin alone, and 21.9% were on combined treatment (Table 2 ). While 21 patients (14.4%) with self-reported glucose dysregulation (diabetes of IFG/IGT) were not treated with any antidiabetic medication, four patients (0.8%) were treated with these drugs, but did not report on diabetes or IFG/ IGT. In patients with dysglycemia, median HbA1c level was 6.7%, with no significant differences between age groups 4 Including statins, fibrates, nicotinic acids, resins, and omega-3 fatty acids 5 In pts. with self-reported dysglycemia (Table 3c) . Sixty percent of patients with dysglycemia had adequate glycemic control, while 53% of younger patients revealed HbA1c levels < 7% under their antidiabetic treatment, as compared to 69% of older individuals (p = 0.06).
Discussion
The current report on secondary prevention for CHD within the German arm of the EUROASPIRE IV survey shows that a majority of CHD patients was treated with the recommended basic drug therapy containing beta-blockers, platelet inhibitors, and statins. Treatment targets for blood pressure and LDL cholesterol levels were not achieved in many patients and glycemic control in diabetic CHD patients with HbA1 levels below 7% was insufficient. We observed a trend towards smoking cessation, but unhealthy lifestyles indicated by overweight/ obesity were still frequent. Patterns of therapeutic care differed between younger CHD patients and patients older than 70 years. Generally, older CHD patients were less likely to receive the recommended pharmacological therapy, exhibited inadequate blood pressure control more often, and were more likely to be diabetic. Nevertheless, a greater proportion of diabetic patients was achieving the HbA1c target, and less elder patients were current smokers or were obese. Representing a global burden, CHD is one of the major causes of mortality, responsible for 15.6 million deaths worldwide [18] . Due to improved health care, mortality rates as well as absolute numbers of death of CHD are decreasing in Europe over the past 10 years, whereas a rise in hospital admissions can be observed [19] [20] [21] . Preventive care measures not only impact on the risk of morbidity and mortality in patients with established heart disease, but also reduce the risk of developing vascular disease in high-risk populations [22, 23] . Patients are increasingly aware of the benefits of a healthy lifestyle, as are providers regarding treatment targets over the last decade. Yet, translation of guideline recommendations in clinical practice remains insufficient [2] .
Guideline recommendations for secondary CHD prevention also apply to patients of older age [1, 22, 24] , but achievement of certain goals may be limited due to conflicting recommendations of various specialties as these patients frequently present with not only one, but multiple conditions [12, 25] .
Unhealthy Lifestyles, Smoking, and Overweight/Obesity
The secular trends observed across Europe regarding unhealthy lifestyle in general, and obesity and smoking in particular among younger patients, were also evident in the current EUROASPIRE IV survey, however, with a wide variation of treatment and behavior patterns. For example, the prevalence of smoking ranged from 7% in Finland to 28% in Cyprus [3] . The prevalence determined for Germany, i.e., about 10% smokers, is promising since it is lower than in previous surveys (16-18%) ; however, about 17% of younger CHD patients were identified as current smokers [13] . In general, these data seem to point towards a subtle national trend towards smoking cessation in the German CHD population [26] . Overweight and obesity represent a major burden in the BWestern world.^It is remarkable that even across very different European communities in EUROASPIRE IV, the vast majority of about 75 to 85% of CHD patients are classified as overweight (BMI > 25 kg/m 2 ). Considerable variability was observed regarding obesity (i.e., BMI > 30 kg/m 2 ) with 26% in Serbia and 49% in Slovenia [3] . In Germany, 85% were overweight and 37% were obese, with higher rates in younger patients, which is overall comparable to trends described for EUROASPIRE I-III [13] and consistent with trends reported previously [27] . The latter study also reported on a lower level of physical activity in older adults, potentially because of frailty, dizziness due to hypotension, and fear of falls. On the other hand, it has been shown that even limited but regular physical activity reduces the risk for CV events even in the elderly [28] .
Medical Treatment in Secondary CHD Prevention
Overall, the vast majority of patients in the EUROASPIRE IV study was being treated with the recommended cardioprotective drug therapy, i.e., platelet inhibitor, beta-blocker, and statin. The German estimates are comparable with the European average [3] . Prescription patterns varied in older vs. younger patients: those older than 70 years were less likely to receive beta-blocker and also platelet inhibitors; however, a greater proportion of anticoagulation therapy was observed in these patients. The latter was related to a greater proportion of older patients with atrial fibrillation. Only about half of older patients received all recommended drug classes simultaneously, while this number was about 70% in younger patients.
It is well known that prescription patterns and adherence to guideline recommendations vary in older patients [29] . These frequently multi-morbid patients present with multiple medications (Bpolypharmacy^), and medical therapy and adherence might be limited by contraindications and side effects [30, 31] . This dilemma of medical need and potential side effects might stop many physicians from prescribing drug classes of secondary CVD prevention as recommended by guidelines. Further, cognitive impairment of the elderly is highly prevalent in older subjects with vascular disease and might impede such efforts [32] . However, adequate CHDspecific pharmacotherapy has been associated with improved outcomes also in older CHD patients. Hence, efforts should be made to prescribe such regimens also in the elderly patient [11, 33, 34] . However, it may take some time to educate physicians that even the elderly benefits from the same secondary prevention therapy that has been developed through clinical trials that were mainly performed on younger individuals.
Blood Pressure Control and Hypertension
Recently, the definition of hypertension and the recommended blood pressure targets were modified and adapted by International and National Societies [15, 35] . Generally, blood pressure values of greater than 140/90 mmHg are considered Bhypertensive,^while even higher values are acceptable for the elderly (150/90 mmHg) to acknowledge comorbid conditions and the risk of hypotension, dizziness, and falls. Therefore, applying the Bold^blood pressure target of 130/ 80 mmHg classified only 29% of German patients (European average 33%) as being within the recommended range [3] . According to updated recommendations, 55% of German CHD patients were within the suggested blood pressure range. Vice versa, 45% in the entire German EUROASPIRE IV sample were not treated adequately, in fact even 50% of patients older than 70 years. It will be interesting to see how the data of the recently published SPRINT trial may change guideline recommendations; in non-diabetic patients with increased CV risk, a blood pressure target as low as 120 mmHg reduced CV events and mortality, in the entire group as well as in the elderly [36] .
Compared to the previous EUROASPIRE surveys, there might be a positive trend over the last decade for more patients being on treatment targets [13] . However, there is considerable variation about valid estimates on the prevalence of uncontrolled hypertension in Germany. Recent data from the DEGS survey suggest that about 80% of subjects in a nationwide representative sample of adults present with controlled blood pressure of < 140/90 mmHg. A similar proportion was observed in patients with self-reported stroke or CHD [37] . A European survey (including Germany) on general practitioners, internists, and cardiologists also reports on comparable numbers between 50 and 60% of patients being treated within the recommended range [38] . Encouraging results have been reported of seven German population-based studies, which indicate lower blood pressure levels and a much better control of hypertensive patients in recent years [39] .
Lipid Control and Dyslipidemia
Although eight to nine out of ten German patients in EUROASPIRE IV were treated with lipid-lowering drugs, mainly statins, only one out of ten reached LDL cholesterol levels < 70 mg/dl, and 60% were below 100 mg/dl. Treating dyslipidemia is a cornerstone of CHD care as it reduces mortality in secondary [40] and primary CHD prevention [41] . Statin treatment is also similarly effective in the elderly as compared to younger individuals [42] . Better translation from guideline recommendations into clinical practice is reflected by increasing numbers of patients on lipid-lowering drugs over the last decade [2, 13] , with now about 80-90% of patients across Europe being on statins [3] . We did not find any evidence that treatment patterns vary between younger and older individuals, neither in prescription rates of lipidlowering agents, nor in accomplishing treatment goals. The importance of tightly controlling LDL levels was further highlighted by lowering the target to < 70 mg/dl by the ESC for all CHD patients in 2013 [1] . Therefore, starting in 2012, EUROASPIRE IV was not able to address this updated recommendation. How national and international campaigns are effective to establishing this strict target level in clinical practice, how it translates in improved outcomes, but also how safe these measures are, is a still open debate and needs to be investigated in future studies. Herein, it should be noted that follow-up LDL measurement and treating patients to a defined LDL target has been questioned recently in clinical practice guidelines [43, 44] , because of sparse evidence that this approach is associated with improved outcomes.
Dysglycemia and Diabetes Mellitus
Disturbances in glucose metabolism and particularly type 2 diabetes are frequently a consequence of obesity, unhealthy diet, and limited physical activity. Diabetes further increases the risk for CV complications and progression of CHD [1] and should thus be detected early on and treated consequently. In the German sample of EUROASPIRE IV, 25% reported diabetes (European average, 27%), an estimate that is as high as never before in German CHD patients enrolled in previous phases of EUROASPIRE [13] . It is known that the prevalence of diabetes is growing in both the developed and developing world, paralleling the rise in obesity rates [45, 46] . In Germany, increasing rates may slow in recent years in the general population, with a fairly stable prevalence of about 9% [47] .
Glycemic control in diabetic patients with CHD is a key component of secondary prevention and HbA1c levels of < 7% are generally recommended [1, 48] . We found that only 60% of diabetic CHD patients were within the target range. Moreover, younger patients were even less likely to be adequately treated for dysglycemia, with more than 50% with HbA1c greater than 7%. This is of particular interest, as the benefits of tight glycemic control outweigh the harms (e.g., hypoglycemic episodes) in younger patients, whereas lessstrict treatment targets have been proposed for the elderly (i.e., HbA1c > 7.5 or > 8.0%) [48, 49] to reflect multimorbidity and the risk of adverse events [50, 51] .
Limitations
The current study has limitations that deserve mentioning. First, our findings were derived from participants of the area of Würzburg and are therefore not generalizable to all CHD patients in Germany. Second, our study sample might even not be representative for all patients admitted for CHD at the recruiting centers, as only 38.8% of invited subjects agreed to participate. Due to data protection regulations, analysis of reasons for non-participation is limited: eligible patients who did not participate in EUROASPIRE IV were more likely to be female and of slightly younger age. Third, it is not possible to unrestrictedly compare our current results of EUROASPIRE IV to the findings of the previous EUROASPIRE surveys I to III in Germany, as the study center and the source population moved from Münster to Würzburg [13] . Thus, secular trends across the German EUROASPIRE phases have to be interpreted with caution. Finally, as EUROASPIRE IV did not include patients older than 79 years at the index event, we are unable to make any assumptions on patients aged 80 years or older, a subgroup that is likely to increase in the next decades due to a longer life expectancy and rising survival rates of CVD events.
Conclusions
Most CHD patients in Germany received the recommended medication for secondary prevention, but treatment targets were not achieved in many patients and patterns varied in the elderly. While the prevalence of smoking was considerably low, overweight/obesity and limited physical activity, particularly in younger individuals, are alarming. Modification of lifestyles may become an even greater factor in prevention campaigns than medical treatment into certain target ranges, but should also consider different needs in older individuals.
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